GOODWILL AND OTHER INTANGIBLE ASSETS (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Total other intangible assets - Gross Carrying Amount	$ 5,436	$ 11,855
Total other intangible assets - Accumulated Amortization	3,118	3,077
Total other intangible assets - Net Carrying Amount	2,318	8,778
Impairment charge for BMS-986094 intangible asset		1,830
Goodwill [Line Items]
Goodwill, Beginning Balance	7,635	5,586
Assets held-for-sale	(550)
Goodwill, Ending Balance	7,096	7,635	5,586
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	4,888	11,187
Finite-Lived Intangible Assets, Accumulated Amortization	3,118	3,077
Finite-Lived Intangible Assets, Net Carrying Amount	1,770	8,110
Impairment charge related to a partial write-down to fair value of developed technology costs related to a non-key product		38
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Estimated future amortization, 2014	300
Estimated future amortization, 2015	200
Estimated future amortization, 2016	200
Estimated future amortization, 2017	200
Estimated future amortization, 2018	150
Estimated future amortization, After 2018	720
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Other intangible assets carrying amount at January 1	8,778	3,124	3,370
Capitalized software and other additions	80	60	75
Acquisitions		8,335	160
Amortization expense	(858)	(607)	(353)
Impairment charges		(2,134)	(30)
Assets held-for-sale	(5,682)
Other			(98)
Other intangible assets carrying amount at December 31	2,318	8,778	3,124
Developed technology rights related to the sale of the diabetes business reclassified to assets held-for-sale	5,562
In-process research and development related to the sale of the diabetes business reclassified to assets held-for-sale	120
In Process Research And Development [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired Indefinite-lived Intangible Asset, Carrying Amount	548	668
Licenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	1,162	1,160
Finite-Lived Intangible Assets, Accumulated Amortization	637	534
Finite-Lived Intangible Assets, Net Carrying Amount	525	626
Licenses [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of intangible asset	5 years 0 months 0 days
Licenses [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of intangible asset	15 years 0 months 0 days
Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	2,486	8,827
Finite-Lived Intangible Assets, Accumulated Amortization	1,482	1,604
Finite-Lived Intangible Assets, Net Carrying Amount	1,004	7,223
Impairment charge related to a partial write-down to fair value of developed technology costs related to a non-key product		120
Technology [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of intangible asset	9 years 0 months 0 days
Technology [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of intangible asset	15 years 0 months 0 days
Capitalized Software [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross Carrying Amount	1,240	1,200
Finite-Lived Intangible Assets, Accumulated Amortization	999	939
Finite-Lived Intangible Assets, Net Carrying Amount	241	261
Capitalized Software [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of intangible asset	3 years 0 months 0 days
Capitalized Software [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life of intangible asset	10 years 0 months 0 days
Amylin Pharmaceuticals, Inc. [Member]
Goodwill [Line Items]
Acquisition		836
Adjustment to goodwill from finalization of Amylin acquisition purchase price allocation	11
Inhibitex, Inc. [Member]
Goodwill [Line Items]
Acquisition		$ 1,213